PortfoliosLab logo
Genelux Corporation (GNLX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US36870H1032

CUSIP

36870H103

IPO Date

Jan 26, 2023

Highlights

Market Cap

$104.90M

EPS (TTM)

-$0.87

Total Revenue (TTM)

$452.00K

Gross Profit (TTM)

-$204.00K

EBITDA (TTM)

-$30.11M

Year Range

$1.60 - $5.89

Target Price

$17.60

Short %

6.24%

Short Ratio

11.76

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Genelux Corporation (GNLX) returned 17.80% year-to-date (YTD) and -27.42% over the past 12 months.


GNLX

YTD

17.80%

1M

13.01%

6M

-7.33%

1Y

-27.42%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.64%

1M

8.97%

6M

-2.62%

1Y

11.90%

5Y*

15.76%

10Y*

10.69%

*Annualized

Monthly Returns

The table below presents the monthly returns of GNLX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202567.37%5.82%-35.41%-0.37%3.35%17.80%
2024-24.48%-31.00%-11.92%-51.63%-12.86%-28.04%0.00%11.28%9.22%35.86%-16.46%-12.27%-83.15%
2023-6.88%159.65%86.55%-12.80%12.44%20.29%-35.61%14.76%1.28%-40.75%-17.99%17.73%127.80%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of GNLX is 41, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of GNLX is 4141
Overall Rank
The Sharpe Ratio Rank of GNLX is 3737
Sharpe Ratio Rank
The Sortino Ratio Rank of GNLX is 4949
Sortino Ratio Rank
The Omega Ratio Rank of GNLX is 4848
Omega Ratio Rank
The Calmar Ratio Rank of GNLX is 3232
Calmar Ratio Rank
The Martin Ratio Rank of GNLX is 3737
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Genelux Corporation (GNLX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Genelux Corporation Sharpe ratios as of May 13, 2025 (values are recalculated daily):

  • 1-Year: -0.24
  • All Time: -0.24

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Genelux Corporation compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Genelux Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Genelux Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Genelux Corporation was 95.74%, occurring on Aug 5, 2024. The portfolio has not yet recovered.

The current Genelux Corporation drawdown is 92.68%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-95.74%Jun 22, 2023282Aug 5, 2024
-51.91%Mar 7, 20235Mar 13, 20237Mar 22, 202312
-24.63%Mar 31, 202331May 15, 202320Jun 13, 202351
-9.59%Jan 27, 20236Feb 3, 20238Feb 15, 202314
-4.56%Mar 23, 20231Mar 23, 20231Mar 24, 20232

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Genelux Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Genelux Corporation, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 13.4% positive surprise.


-0.50-0.40-0.30-0.20-0.100.00AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025
-0.21
-0.24
Actual
Estimate

Valuation

The Valuation section provides an overview of how Genelux Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for GNLX relative to other companies in the Biotechnology industry. Currently, GNLX has a P/S ratio of 12,362.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for GNLX in comparison with other companies in the Biotechnology industry. Currently, GNLX has a P/B value of 3.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items